# Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Canonical URL: https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering
Ticker: TNGX
Company: Tango Therapeutics
Source: Tango Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.tangotx.com
## Summary

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares

## Article Body
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares
## Recent Company News
- 2026-06-25 13:46 EST — [Tango Therapeutics Appoints Robert Azelby to Board of Directors](https://biopharmsignal.com/news/TNGX/tango-therapeutics-appoints-robert-azelby-to-board-of-directors) — Source: Tango Therapeutics
- 2026-06-25 13:46 EST — [Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering) — Source: Tango Therapeutics
- 2026-06-25 13:46 EST — [Tango Therapeutics Announces Proposed $500 Million Public Offering](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-proposed-500-million-public-offering) — Source: Tango Therapeutics
- 2026-06-25 13:46 EST — [Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-combination-of-vopimetostat-and-daraxonrasib-demonstrated-92-objective-response-rate-in-pancreatic-cancer) — Source: Tango Therapeutics
- 2026-06-25 13:46 EST — [Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights](https://biopharmsignal.com/news/TNGX/tango-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights) — Source: Tango Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)